Mabwell (Shanghai) Bioscience Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Public, Subsidiary
- Established
- 2017-05-12
- Employees
- 1.4K
- Market Cap
- -
- Website
- https://www.mabwell.com
A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2022-06-13
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 216
- Registration Number
- NCT05416749
- Locations
- 🇨🇳
The first affiliated hospital of bengbu medicial college, Bengbu, Anhui, China
🇨🇳Hunan cancer hospital, Changsha, Hunan, China
🇨🇳Jian Zhang, Shanghai, Shanghai, China
A Phase â…¡ Clinical Study of 9MW1411 Injection in Acute Bacterial Skin and Skin Structure Infections
- First Posted Date
- 2022-04-21
- Last Posted Date
- 2022-04-21
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT05339802
- Locations
- 🇨🇳
Huashan Hospital affiliated to Fudan University, Shanghai, Shanghai, China
Efficacy and Safety of 9MW0813 in Subjects With Diabetic Macular Edema
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 346
- Registration Number
- NCT05324774
- Locations
- 🇨🇳
Beijing tongren hospital affliated to capital medical university, Beijing, Beijing, China
Safety and Efficacy of 9MW0813 in Subjects With Diabetic Macular Edema
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05324592
- Locations
- 🇨🇳
Beijing tongren hospital affliated to capital medical university, Beijing, Beijing, China
A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 433
- Registration Number
- NCT05297292
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Si Chuan, China
A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid Tumors
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 208
- Registration Number
- NCT05216965
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Efficacy and Safety of MW031 in PMO Subjects
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 448
- Registration Number
- NCT05215977
- Locations
- 🇨🇳
Peking Union Hospital, Beijing, Beijing, China
A Clinical Study in Healthy Subjects to Evaluate 9MW1911 Injection
- Conditions
- Interventions
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT05170243
- Locations
- 🇨🇳
Shanghai Public Health Center, Shanghai, Shanghai, China
A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2022-05-09
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 272
- Registration Number
- NCT05048160
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China
Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid Tumors
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 708
- Registration Number
- NCT04812509
- Locations
- 🇨🇳
Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China